- Home
- RMI vs INMB Comparison
RMI vs INMB Comparison
Compare RMI & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.77
Company Overview
Basic Information| Metric | RMI | INMB |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.6M | 49.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RMI | INMB |
|---|---|---|
| Price | $14.39 | $1.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.30 |
| AVG Volume (30 Days) | 17.4K | ★ 503.1K |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 7.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | $173.21 |
| Revenue Next Year | N/A | $12,733.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.05 |
| 52 Week Low | $13.05 | $1.38 |
| 52 Week High | $17.37 | $11.64 |
Technical Indicators
Market Signals| Indicator | RMI | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 47.50 |
| Support Level | $14.33 | $1.75 |
| Resistance Level | $14.52 | $1.90 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 4.00 | 11.67 |
Price Performance
Historical Comparison RMI
INMB
About RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.